HUT76623A - Stabilization of peptides and proteins for radiopharmaceutical use - Google Patents

Stabilization of peptides and proteins for radiopharmaceutical use Download PDF

Info

Publication number: HUT76623A
Authority: HU; Hungary
Prior art keywords: protein; radiolabeled; diagnostic; polypeptide; composition
Prior art date: 1994-03-16

Application number

HU9602554A

Other languages

English (en)

Hungarian (hu)

Other versions

HU9602554D0 (en

Inventor

Kathleen M Miller

La Fourniere Laurence De

Original Assignee

Mallinckrodt Medical Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-16

Filing date

1995-03-16

Publication date

1997-10-28

1995-03-16 Application filed by Mallinckrodt Medical Inc filed Critical Mallinckrodt Medical Inc

1996-11-28 Publication of HU9602554D0 publication Critical patent/HU9602554D0/hu

1997-10-28 Publication of HUT76623A publication Critical patent/HUT76623A/hu

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 91
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 63
102000004169 proteins and genes Human genes 0.000 title claims abstract description 54
108090000623 proteins and genes Proteins 0.000 title claims abstract description 54
230000006641 stabilisation Effects 0.000 title claims description 5
238000011105 stabilization Methods 0.000 title claims description 5
229940121896 radiopharmaceutical Drugs 0.000 title 1
239000012217 radiopharmaceutical Substances 0.000 title 1
230000002799 radiopharmaceutical effect Effects 0.000 title 1
239000000203 mixture Substances 0.000 claims abstract description 57
239000004094 surface-active agent Substances 0.000 claims abstract description 41
150000003839 salts Chemical class 0.000 claims abstract description 22
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 44
229920001184 polypeptide Polymers 0.000 claims description 32
238000000034 method Methods 0.000 claims description 24
229920000053 polysorbate 80 Polymers 0.000 claims description 23
150000001875 compounds Chemical class 0.000 claims description 22
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 22
238000003608 radiolysis reaction Methods 0.000 claims description 22
239000011780 sodium chloride Substances 0.000 claims description 22
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 21
229940068968 polysorbate 80 Drugs 0.000 claims description 21
238000002360 preparation method Methods 0.000 claims description 19
230000001225 therapeutic effect Effects 0.000 claims description 18
239000013522 chelant Substances 0.000 claims description 11
239000002736 nonionic surfactant Substances 0.000 claims description 11
239000003945 anionic surfactant Substances 0.000 claims description 10
239000003093 cationic surfactant Substances 0.000 claims description 10
241001465754 Metazoa Species 0.000 claims description 9
125000002091 cationic group Chemical group 0.000 claims description 9
239000002888 zwitterionic surfactant Substances 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 6
230000000087 stabilizing effect Effects 0.000 claims description 6
238000002059 diagnostic imaging Methods 0.000 claims description 5
238000002405 diagnostic procedure Methods 0.000 claims description 3
125000000129 anionic group Chemical group 0.000 claims 8
230000001939 inductive effect Effects 0.000 claims 1
229940127043 diagnostic radiopharmaceutical Drugs 0.000 abstract description 3
229940127044 therapeutic radiopharmaceutical Drugs 0.000 abstract description 3
239000000243 solution Substances 0.000 description 29
210000001519 tissue Anatomy 0.000 description 18
230000002285 radioactive effect Effects 0.000 description 15
238000009472 formulation Methods 0.000 description 12
CNLWNYCFDMAZCB-HUVROIHYSA-N 2-[2-[[2-[[(2r)-1-[[(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-16-benzyl-4-[[(2r,3r)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phe Chemical compound C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)NC(=O)CN(CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)CC(O)=O)C1=CC=CC=C1 CNLWNYCFDMAZCB-HUVROIHYSA-N 0.000 description 11
239000003381 stabilizer Substances 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
230000015556 catabolic process Effects 0.000 description 7
238000006731 degradation reaction Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
238000004128 high performance liquid chromatography Methods 0.000 description 6
238000002372 labelling Methods 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 5
238000010438 heat treatment Methods 0.000 description 5
239000007788 liquid Substances 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
239000000047 product Substances 0.000 description 5
230000005855 radiation Effects 0.000 description 5
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 4
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
108010016076 Octreotide Proteins 0.000 description 4
239000002738 chelating agent Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
229960002700 octreotide Drugs 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
102000008100 Human Serum Albumin Human genes 0.000 description 3
108091006905 Human Serum Albumin Proteins 0.000 description 3
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
230000001588 bifunctional effect Effects 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
229910052802 copper Inorganic materials 0.000 description 3
239000010949 copper Substances 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
238000003384 imaging method Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000003446 ligand Substances 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
239000012460 protein solution Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
108050001286 Somatostatin Receptor Proteins 0.000 description 2
102000011096 Somatostatin receptor Human genes 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
239000003708 ampul Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
238000002314 autoradiolysis reaction Methods 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
238000002144 chemical decomposition reaction Methods 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
229960005219 gentisic acid Drugs 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229910052738 indium Inorganic materials 0.000 description 2
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
229960000367 inositol Drugs 0.000 description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
239000000693 micelle Substances 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
229910052702 rhenium Inorganic materials 0.000 description 2
WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 2
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229960002898 threonine Drugs 0.000 description 2
238000012546 transfer Methods 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical group C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
ORLFVWPPBMVPNZ-UHFFFAOYSA-N 1-(6-methylheptyl)-4-[4-(6-methylheptyl)phenoxy]benzene Chemical compound C1=CC(CCCCCC(C)C)=CC=C1OC1=CC=C(CCCCCC(C)C)C=C1 ORLFVWPPBMVPNZ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
229910052692 Dysprosium Inorganic materials 0.000 description 1
NVTRPRFAWJGJAJ-UHFFFAOYSA-L EDTA monocalcium salt Chemical compound [Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O NVTRPRFAWJGJAJ-UHFFFAOYSA-L 0.000 description 1
GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
MOIJZWWOFOQFMH-UHFFFAOYSA-M Gentisic acid sodium Chemical compound [Na+].OC1=CC=C(O)C(C([O-])=O)=C1 MOIJZWWOFOQFMH-UHFFFAOYSA-M 0.000 description 1
229910052689 Holmium Inorganic materials 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229910052772 Samarium Inorganic materials 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
GTDPSWPPOUPBNX-UHFFFAOYSA-N ac1mqpva Chemical compound CC12C(=O)OC(=O)C1(C)C1(C)C2(C)C(=O)OC1=O GTDPSWPPOUPBNX-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
-1 calcium 2 * Chemical class 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
229960002303 citric acid monohydrate Drugs 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000005138 cryopreservation Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
229910052733 gallium Inorganic materials 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229960003330 pentetic acid Drugs 0.000 description 1
239000003186 pharmaceutical solution Substances 0.000 description 1
239000007971 pharmaceutical suspension Substances 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000941 radioactive substance Substances 0.000 description 1
230000003439 radiotherapeutic effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
239000010948 rhodium Substances 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229950004644 sodium gentisate Drugs 0.000 description 1
239000001433 sodium tartrate Substances 0.000 description 1
229960002167 sodium tartrate Drugs 0.000 description 1
235000011004 sodium tartrates Nutrition 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
229910052712 strontium Inorganic materials 0.000 description 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
150000007944 thiolates Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
150000003667 tyrosine derivatives Chemical class 0.000 description 1
238000012800 visualization Methods 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Optics & Photonics (AREA)
Pharmacology & Pharmacy (AREA)
Physics & Mathematics (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HU9602554A 1994-03-16 1995-03-16 Stabilization of peptides and proteins for radiopharmaceutical use HUT76623A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US21434794A	1994-03-16	1994-03-16

Publications (2)

Publication Number	Publication Date
HU9602554D0 HU9602554D0 (en)	1996-11-28
HUT76623A true HUT76623A (en)	1997-10-28

Family

ID=22798713

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU9602554A HUT76623A (en)	1994-03-16	1995-03-16	Stabilization of peptides and proteins for radiopharmaceutical use

Country Status (8)

Country	Link
US (1)	US6174513B1 (fr)
EP (1)	EP0763056B1 (fr)
JP (1)	JP3812680B2 (fr)
AT (1)	ATE195322T1 (fr)
CA (1)	CA2185653C (fr)
DE (1)	DE69518319T2 (fr)
HU (1)	HUT76623A (fr)
WO (1)	WO1995025119A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020187099A1 (en) *	2001-05-16	2002-12-12	Rajesh Manchanda	Stabilization of radionuclide-containing compositions
ITBA20020032A1 (it) *	2002-09-24	2004-03-25	Bio D Soc	Metodo per stabilizzare le proteine per la conservazione ad alte temperature.
WO2010121133A2 (fr)	2009-04-17	2010-10-21	The General Hospital Corporation	Imagerie multimodale de fibrine
BRPI1009900A2 (pt)	2009-03-19	2016-03-15	Wyeth Llc	métodos para a preparação de ácido [2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)etil]fosfônico e seus precursores
WO2011147762A2 (fr)	2010-05-25	2011-12-01	Bayer Pharma Aktiengesellschaft	Composition radiopharmaceutique stabilisée
JP6520948B2 (ja) *	2014-08-08	2019-05-29	日油株式会社	蛋白質安定化剤及び蛋白質安定化方法
KR20220063218A (ko)	2019-09-16	2022-05-17	노파르티스 아게	안정한 농축 방사성 약제학적 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0012926B1 (fr) *	1978-12-19	1984-03-07	Byk Gulden Lomberg Chemische Fabrik GmbH	Solutions d'agents de contraste pour rayons X
US4853330A (en) *	1983-04-07	1989-08-01	Genentech, Inc.	Human tissue plasminogen activator
US4479930A (en) *	1982-07-26	1984-10-30	Trustees Of The University Of Massachusetts	Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4457916A (en) *	1982-08-31	1984-07-03	Asahi Kasei Kogyo Kabushiki Kaisha	Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
CA2066779A1 (fr) *	1989-09-22	1991-03-23	Jean-Luc Vanderheyden	Compositions a base de radionucleides therapeutiques stables, et leurs methodes de preparation
DE59010815D1 (de) *	1989-12-27	1998-04-23	Boehringer Ingelheim Int	Verwendung eines antikoagulant als diagnostikum
US5080883A (en) *	1990-05-11	1992-01-14	Mallinckrodt, Inc.	99 mtcn3s-conjugated anti-bibrin monoclonal antibody as an in vivo diagnostic agent for imaging
US5328898A (en) *	1990-06-22	1994-07-12	Duke University	Factor XIIIA fibrin binding fragments
US5843463A (en) *	1990-12-21	1998-12-01	Antexbiologics, Inc.	Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
US5763585A (en) *	1993-10-13	1998-06-09	Anergen, Inc.	Method of making MHC-peptide complexes using metal chelate affinity chromatography
US5628981A (en) *	1994-12-30	1997-05-13	Nano Systems L.L.C.	Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents

1995
- 1995-03-16 JP JP52413995A patent/JP3812680B2/ja not_active Expired - Fee Related
- 1995-03-16 CA CA002185653A patent/CA2185653C/fr not_active Expired - Fee Related
- 1995-03-16 AT AT95914715T patent/ATE195322T1/de not_active IP Right Cessation
- 1995-03-16 DE DE69518319T patent/DE69518319T2/de not_active Expired - Fee Related
- 1995-03-16 EP EP95914715A patent/EP0763056B1/fr not_active Expired - Lifetime
- 1995-03-16 WO PCT/US1995/003180 patent/WO1995025119A1/fr not_active Ceased
- 1995-03-16 HU HU9602554A patent/HUT76623A/hu unknown
1998
- 1998-07-30 US US09/126,545 patent/US6174513B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69518319D1 (de)	2000-09-14
EP0763056B1 (fr)	2000-08-09
CA2185653A1 (fr)	1995-09-21
EP0763056A4 (fr)	1997-07-30
WO1995025119A1 (fr)	1995-09-21
HU9602554D0 (en)	1996-11-28
EP0763056A1 (fr)	1997-03-19
JPH09510454A (ja)	1997-10-21
CA2185653C (fr)	2009-01-13
US6174513B1 (en)	2001-01-16
DE69518319T2 (de)	2000-12-14
ATE195322T1 (de)	2000-08-15
JP3812680B2 (ja)	2006-08-23

Legal Events

Date	Code	Title	Description
1999-01-28	DFC4	Cancellation of temporary protection due to refusal

Publication	Publication Date	Title
EP0600992B1 (fr)	2000-09-20	Utilisation de l'acide gentisique ou de l'alcool gentisyle pour stabiliser des peptides et proteines radiomarques
EP0570493B1 (fr)	2000-01-05	POLYPEPTIDES MARQUES AU TECHNETIUM 99m POUR LES TECHNIQUES D'IMAGERIE
US5753205A (en)	1998-05-19	Radiolabelled peptide compounds
US5219556A (en)	1993-06-15	Stabilized therapeutic radiopharmaceutical complexes
RU2343965C2 (ru)	2009-01-20	Способ получения галлия-68, его использование, а также устройство для осуществления указанного способа
EP3268337B1 (fr)	2020-04-01	Procédés et trousses de préparation de complexes de radionucléides
KR100650506B1 (ko)	2006-11-30	방사성 의약품용 레늄-트리카보닐 착물 및 그 전구체의제조방법
EP2658581B1 (fr)	2018-05-30	Conjugué d'albumine humaine et d'acide 2-(4-isothiocyanatobenzyl)-1,4,7,10-tétraazacyclododécane-1,4,7,10-tétra acétique utile pour la localisation de radionucléides pour des fins diagnostiques et thérapeutiques
EP1771209B1 (fr)	2012-08-15	Agents radiopharmaceutiques stabilisés et lyophilisés
KR101108420B1 (ko)	2012-01-30	방사성표지된 갈륨 착물의 마이크로파 제조 방법
JPH0772144B2 (ja)	1995-08-02	制菌剤含有放射性診断用剤
JP3812680B2 (ja)	2006-08-23	放射性医薬用途のペプチド類およびタンパク質類の安定化
Wang et al.	2020	Preclinical evaluation of cationic DOTA-triarginine-lipid conjugates for theranostic liquid brachytherapy
CN116472068A (zh)	2023-07-21	治疗性放射性标记的缀合物及其在疗法中的用途
US5879660A (en)	1999-03-09	Radiolabeled glucans which bind to leukocytes, sites of infection, inflammation, atherosclerosis, or cancer
US20030021749A1 (en)	2003-01-30	Treatment of cancer and other diseases by administration of positron-emitting radiopharmaceuticals
JP2025541803A (ja)	2025-12-23	アルファエミッタ標識化ソマトスタチン受容体アンタゴニスト
US20070248533A1 (en)	2007-10-25	Stabilized and Lyophilized Radiopharmaceutical Agents For Destroying Tumors
WO2023202730A2 (fr)	2023-10-26	Solution aqueuse pharmaceutique dérivée de bleu d'evans radioactif, son procédé de préparation et son utilisation
JP2864448B2 (ja)	1999-03-03	安定な放射性テクネチウム標識診断用組成物
AU658617C (en)	1995-11-09	Technetium-99m labeled polypeptides for imaging
WO2006009891A1 (fr)	2006-01-26	Procédé de traitement de patients en utilisant des agents radio pharmaceutiques stabilisés et lyophilisés
EP1343534A2 (fr)	2003-09-17	Traitement du cancer avec des produits radiopharmaceutiques emettant des positrons
AU1429392A (en)	1992-09-15	In situ synthesis of radiopharmaceuticals